Richard J Cook
Overview
Explore the profile of Richard J Cook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
240
Citations
2942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kharouf F, Gao S, Pereira D, Rosen C, Cook R, Chandran V, et al.
Semin Arthritis Rheum
. 2025 Mar;
72:152701.
PMID: 40068527
Objectives: Tuft resorption (TR) is an important radiographic feature of psoriatic arthritis (PsA). We aimed to define the prevalence of TR in patients with PsA, the clinical and radiographic features...
2.
Kharouf F, Gao S, Pereira D, Cook R, Chandran V, Gladman D
J Rheumatol
. 2025 Feb;
PMID: 39955091
Objective: We aimed to explore the prevalence of degenerative disc disease (DDD) in patients with psoriatic arthritis (PsA) aged < 50 years and to describe the factors associated with its...
3.
Kharouf F, Gao S, Al-Matar S, Cook R, Chandran V, Gladman D
RMD Open
. 2024 Nov;
10(4).
PMID: 39510763
Objectives: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). We aimed to define the prevalence of CKD in patients with PsA, describe their long-term renal outcomes and...
4.
Gutierrez J, Thib S, Koppikar S, Cook R, Eder L
RMD Open
. 2024 Oct;
10(4).
PMID: 39477347
Objective: To investigate the association between musculoskeletal sonographic features and clinical features, as well as treatment outcomes, in patients with active psoriatic arthritis (PsA). Methods: A prospective cohort study was...
5.
Buhler A, Cook R, Lawless J
Stat Med
. 2024 Oct;
43(29):5513-5533.
PMID: 39468894
Regression analyses based on transformations of cumulative incidence functions are often adopted when modeling and testing for treatment effects in clinical trial settings involving competing and semi-competing risks. Common frameworks...
6.
Cook R, Lawless J
Biostatistics
. 2024 Oct;
26(1).
PMID: 39462279
In life history analysis of data from cohort studies, it is important to address the process by which participants are identified and selected. Many health studies select or enrol individuals...
7.
Stringer A, Akkaya Hocagil T, Cook R, Ryan L, Jacobson S, Jacobson J
Biometrics
. 2024 Sep;
80(3).
PMID: 39282733
Benchmark dose analysis aims to estimate the level of exposure to a toxin associated with a clinically significant adverse outcome and quantifies uncertainty using the lower limit of a confidence...
8.
Cook R, Lawless J
Clin Trials
. 2024 Aug;
21(5):604-611.
PMID: 39180288
Clinical trials with random assignment of treatment provide evidence about causal effects of an experimental treatment compared to standard care. However, when disease processes involve multiple types of possibly semi-competing...
9.
Boher J, Filleron T, Sfumato P, Bunouf P, Cook R
Stat Methods Med Res
. 2024 Jun;
33(7):1137-1151.
PMID: 38840446
Despite the widespread use of Cox regression for modeling treatment effects in clinical trials, in immunotherapy oncology trials and other settings therapeutic benefits are not immediately realized thereby violating the...
10.
Akkaya Hocagil T, Ryan L, Cook R, Dang K, Carter R, Richardson G, et al.
Risk Anal
. 2024 Apr;
44(10):2415-2428.
PMID: 38651726
While benchmark dose (BMD) methodology is well-established for settings with a single exposure, these methods cannot easily handle multidimensional exposures with nonlinear effects. We propose a framework for BMD analysis...